In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania
Zameer Mohamed, Jessie Mbwambo, John Rwegasha, Nicodem Mgina, Basra Doulla, Promise Mwakale, Edouard Tuaillon, Stéphane Chevaliez, Yusuke Shimakawa, Simon Taylor-robinson, et al.

To cite this version:

HAL Id: hal-02418324
https://hal.umontpellier.fr/hal-02418324
Submitted on 19 Dec 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania

Zameer Mohamed1 | Jessie Mbwambo2 | John Rwegasha3 | Nicodem Mgina4 | Basra Doulla4 | Promise Mwakale5 | Edouard Tuillon6,7 | Stephane Chevaliez8 | Yusuke Shimakawa9 | Simon D. Taylor-Robinson1 | Mark R. Thursz1 | Ashley S. Brown1 | Maud Lemoine1

1Department of Hepatology, Imperial College London, St Mary’s Hospital, London, UK
2Department of Psychiatry, Muhimbili National Hospital, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
3Department of Gastroenterology, Muhimbili National Hospital, Dar es Salaam, Tanzania
4Tanzania Central Tuberculosis Reference Laboratory, Muhimbili National Hospital, Dar es Salaam, Tanzania
5Department of Bioethics, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
6INSERM U 1058, Université Montpellier 1, Montpellier, France
7Département de Bactériologie-Virologie, CHU Montpellier, Montpellier, France
8Department of Virology, French National Reference Center for Viral Hepatitis B, C and Delta, Hospital Henri Mondor, Université Paris-Est, Créteil, France
9Unité d’Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France

Correspondence
Dr Zameer Mohamed, Department of Surgery and Cancer, Liver and Antiviral Unit, Imperial College London (St Mary’s Campus), South Wharf Road, London W2 1NY, UK.
Email: zm204@ic.ac.uk

Funding information
Wellcome Trust; Imperial College London

Handling editor: Gregory Dore

Abstract

Background: Although novel hepatitis C virus (HCV) RNA point-of-care technology has the potential to enhance the diagnosis in resource-limited settings, very little real-world validation of their utility exists. We evaluate the performance of HCV RNA quantification using the Xpert® HCV viral load Fingerstick assay (Xpert® HCV VL Fingerstick assay) as compared to the World Health Organisation pre-qualified plasma Xpert® HCV VL assay among people who inject drugs (PWID) attending an opioid agonist therapy (OAT) clinic in Dar-es-Salaam, Tanzania.

Methods: Between December 2018 and February 2019, consecutive HCV seropositive PWID attending the OAT clinic provided paired venous and Fingerstick samples for HCV RNA quantification. These were processed onsite using the GeneXpert® platform located at the Central tuberculosis reference laboratory.

Results: A total of 208 out of 220 anti-HCV-positive participants recruited (94.5%) had a valid Xpert® HCV VL result available; 126 (61%; 95% CI 53.8-67.0) had detectable and quantifiable HCV RNA. About 188 (85%) participants had paired plasma and Fingerstick whole blood samples; the sensitivity and specificity for the quantification of HCV RNA levels were 99.1% and 98.7% respectively. There was an excellent correlation ($R^2 = .95$) and concordance (mean difference 0.13 IU/mL, (95% CI −0.9 to 0.16 IU/mL) in HCV RNA levels between plasma samples and Fingerstick samples.

Conclusion: This study found excellent performance of the Xpert® HCV VL Fingerstick assay for HCV RNA detection and quantification in an African-field setting. Its clinical utility represents an important watershed in overcoming existing challenges to HCV diagnosis, which should play a crucial role in HCV elimination in Africa.

Keywords
hepatitis C virus (HCV) diagnosis, people who inject drugs (PWID), point-of-care (POC), sub-Saharan Africa, Xpert
The advent of highly efficacious direct-acting antivirals (DAAs) has provided a springboard to raise the awareness of hepatitis C virus (HCV) as a global health issue and acted as a catalyst to the development of the 2030 World Health Organisation (WHO) viral hepatitis elimination targets. However, currently the majority of infected individuals (80%) remain undiagnosed especially in low-and middle-income countries (LMICs) and only a minority (2% annually) are accessing treatment. As a result, only a handful of countries are currently on track to achieve the ambitious elimination objectives. Thus, a great deal of emphasis has been placed on scaling-up simplified strategies for HCV screening and linkage-to-care.

As LMICs represent 80% of the global HCV epidemic, it is clear that an increased focus is required to address the challenges of case-finding and treatment in these commonly resource-limited settings. Recent times have seen the WHO prequalification of DAAs to ensure the quality control, and fierce competition from generic manufacturers has resulted in a sharp reduction in cost of treatment. Ironically, in many resource-limited settings the cost of diagnosis exceeds the cost of treatment. As HCV RNA confirmation is a pre-requisite for commencing treatment, it is not surprising that access to simple HCV diagnostics in such challenging settings has been underlined as a key priority in order to achieve HCV elimination.

However, the resounding limited access to HCV RNA nucleic acid testing (NAT) in LMICs was emphasised by a recent WHO survey, which reported that 40% of LMICs do not have access to HCV NAT. One of the novel solutions to mitigate the dependence on skilled laboratories and personnel is the emergence of simple point-of-care tests for HCV RNA. Currently, two CE-in vitro diagnostic point-of-care platforms (Genedrive® and Xpert® (Cepheid) for HCV RNA NAT in plasma exist, with one (Xpert®) receiving WHO prequalification in 2017.

However, with the existing point-of-care tests there still remains the issue of plasma separation. Whole blood samples of 50-70 µL have been demonstrated as an alternative method to decentralise and simplify sample collection using dried blood spots (DBS). This is particularly beneficial in rural settings and in people who inject drugs (PWID), where venous access is challenging. In addition, the ease of obtaining a sample can allow task-shifting to a diverse range of healthcare and non-clinical staff. DBS have also been validated for HCV RNA quantification on the new Hologic Aptima assay as well as HCV core antigen quantification on the Abbott Architect platform, reporting sensitivities of 96.4% and 76.1% respectively. Furthermore, a Fingerstick assay using 100 µL has recently been validated for the Xpert® system (Xpert® HCV viral load [VL] Fingerstick assay), which has a lower limit of detection of 40 IU/mL and lower limit of quantification of 100 IU/mL. When compared with the Genedrive® device, not only does the Xpert® HCV VL Fingerstick assay have a superior threshold for HCV RNA detection and avoid the need for any sample preparation, it also has a faster turnaround time (60 minutes vs 90 minutes) and is half the price. All of which make it quite an attractive proposition to improve the access to HCV RNA testing in resource-limited settings.
DAA therapy is available on a private basis only, which is not readily accessible to HCV-infected PWID. In order to assess the performance of HCV RNA quantification, all clients with a known positive result for anti-HCV antibody attending the clinic for OAT, irrespective of concomitant illicit drug use, were invited to participate in the study between December 2018 and February 2019.

2.2 | Ethical considerations

This study received clearance from the respective institutional review board at MNH (ref: MNH/IRB/1/2018/178). All participants provided written informed consent in line with good clinical practice.

2.3 | Clinical assessment and sample collection

All recruited individuals completed a comprehensive demographic and risk factor-based questionnaire, which was administered by a trained fieldworker. All participants then provided paired blood samples. Venous samples were obtained to fill a 4 mL ethylenediamine tetraacetate (EDTA) bottle, while a 100 µL finger-prick sample was collected in an EDTA-coated capillary (Minivette®; Sarstedt) (www.sarstedt.com) and applied directly into the Xpert® HCV VL Fingerstick assay cartridge in line with the manufacturer’s specifications (Cepheid).15 All samples were then delivered to the onsite Central TB Reference Laboratory at MNH for processing on the day of sample collection.

2.4 | Laboratory processing and virological assessment

Laboratory staff prioritised processing Xpert® HCV VL Fingerstick assay samples on the same day as receipt on the GeneXpert® II platform in accordance with the manufacturer’s guidance, to provide a quantitative HCV RNA result within 60 minutes. All venous samples were kept at 4°C for a maximum of 72 hours prior to plasma separation, 1mL was applied to the Xpert® HCV VL cartridge before being processed for HCV RNA quantification on the GeneXpert® II platform in accordance with the manufacturer’s guidance. All residual plasma was stored at –80°C. In the event that either plasma or finger sample failed, where possible a repeat paired sample was collected and run on the Xpert® platform.

2.5 | HCV genotyping

Where available historic HCV genotype was used as previously reported.13 Previously described methods were used to perform sequencing of the HCV genome NS5B region and subsequent phylogenetic analysis.21

2.6 | Sample size calculation

We aimed to demonstrate that a lower boundary of a 95% confidence interval of the diagnostic sensitivity of Xpert® HCV VL Fingerstick assay is at least higher than 90% with a power of 80%. Assuming that the prevalence of chronic HCV infection is 60%-80% in anti-HCV antibody-positive patients, and the true sensitivity of Xpert® HCV VL Fingerstick assay is 97%, we needed to recruit at least 184 anti-HCV-positive patients.

2.7 | Statistical analysis

Characteristics of the study participants were presented by mean, standard deviation, while non-parametric continuous variables were presented by median and interquartile range (IQR) and compared using the Mann-Whitney U test. Categorical variables were presented by percentage. Accuracy of Xpert® HCV VL Fingerstick assay to correctly identify HCV RNA-positive patients was presented by sensitivity and specificity. Correlation and agreement of HCV RNA quantification between Xpert® HCV RNA plasma and Xpert® HCV VL Fingerstick assay were presented by Pearson’s correlation coefficient and Bland Altman analysis respectively. All statistical analyses were completed using Microsoft Excel 2010 and SPSS statistical software version 24.0.

3 | RESULTS

3.1 | Participant characteristics

During the study period, 220 anti-HCV positive patients agreed to participate. The cohort was overwhelmingly male (98%) and had a median age of 41 years (IQR: 37-45). All had a past history of injecting drug use, on average clients started to inject drugs at the age of 23 years with 38% admitted to having ever-shared needles in the past. The median length of time enrolled in the OAT at the time of recruitment was 5 years. The study population characteristics are presented in Table 1.

3.2 | HCV RNA assessment

About 208 of the 220 (95%) of clients enrolled in the study had a valid plasma Xpert® HCV VL result. Of the 12 (5%) without a valid reference HCV RNA result, a venous sample could not be obtained in 8 (4%) clients owing to difficult venous access, three (1%) clients failed owing to inadequate sample volume and one failed owing to a power cut during sample processing. One hundred and twenty-six clients had quantifiable HCV RNA, resulting in a prevalence of chronic HCV infection of 61% (95% CI 54-67). All viraemic patients had quantifiable HCV RNA, with a median HCV RNA level of 6.1 log IU/mL (range; 1.4-7.5). Genotype was available for 53 (42%), with
genotype 1a identified in 35 of 53 cases (66%) and genotype 4a in 18 of 53 (34%) cases respectively (Figure 1).

### 3.3 Repeat sampling and error rates

Overall 71 (32%) of patients required repeat testing owing to test errors (30/71 (42%) Xpert® HCV VL Fingerstick assay only, 28/71 (40%) plasma Xpert® HCV VL only and 13/71 (18%) both assays). In the case of plasma Xpert® HCV VL, 21 of 41 (51%) patients were related to sample volume errors and 20 of 41 (49%) were related to technical failure, which in most cases was owing to instrument interruption after a power shortage. In comparison, all 43 (100%) of the Xpert® HCV VL Fingerstick assay errors were related to inadequate sample volume. Consequently, 32 of 220 (14.5%) patients did not have a paired sample; 4 of 220 (2%) had no sample, 20 of 220 (9%) had a plasma sample only and 8 of 220 (4%) had a Fingerstick sample only (Figures 1 and 2).

Date of plasma Xpert® HCV VL and Xpert® HCV VL Fingerstick testing was available for 213 of 220 (97%) and 206 of 220 (94%). For plasma Xpert® HCV VL and Xpert® HCV VL Fingerstick, errors occurred in 13 of 65 (19%) and 7 of 65 (11%) tests in December, 28 of 130 (22%); and 28 of 126 (22%) tests in January; and none of the 14 (0%) and 4 of 15 (27%) in February respectively. Date of testing was not available for the additional four error samples that occurred in Xpert® HCV VL Fingerstick testing.

### 3.4 Performance of Xpert® HCV RNA Fingerstick assay

About 188 (85%) of those enrolled had paired plasma and fingerstick samples analysed. Viraemia was considered if HCV RNA was both detected and quantified in using each respective test. Overall the Xpert® HCV VL Fingerstick assay performed excellently, with

---

**TABLE 1** Anti-HCV-positive participant characteristics (n = 220)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Result (N = 220)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, y (IQR)</td>
<td>41 (37-45)</td>
</tr>
<tr>
<td>Male sex (n, %)</td>
<td>216 (98)</td>
</tr>
<tr>
<td>HIV co-infection (n, %)</td>
<td>67/185 (36)</td>
</tr>
<tr>
<td>Median age starting injecting drugs (IQR)</td>
<td>23 (20-27)</td>
</tr>
<tr>
<td>Needle sharing (n, %)</td>
<td>69/182 (38)</td>
</tr>
<tr>
<td>Median years on opioid substitution therapy (IQR)</td>
<td>7 (5-8)</td>
</tr>
<tr>
<td>Positive HCV RNA (n, %)</td>
<td>126/208 (61)</td>
</tr>
<tr>
<td>Median HCV RNA viral load (range) (log IU/mL)</td>
<td>6.1 (1.4-7.5)</td>
</tr>
<tr>
<td>Genotype (n, %)</td>
<td></td>
</tr>
<tr>
<td>1a</td>
<td>35/53 (66)</td>
</tr>
<tr>
<td>4a</td>
<td>18/53 (34)</td>
</tr>
</tbody>
</table>

Abbreviations: HCV, hepatitis C virus; IQR, interquartile range.
The challenges of accessing NAT for HCV RNA confirmation has been raised as a key barrier to improving diagnosis in resource-limited settings in sub-Saharan Africa and more specifically in the PWID population in Tanzania. In this study we report the excellent performance of the Xpert® HCV VL Fingerstick assay to confirm viraemic HCV infection. Indeed, our results are consistent with the findings from Lamoury and colleagues, who reported a sensitivity of 98.3% and a specificity of 100% of the Xpert® HCV VL Fingerstick assay to detect HCV RNA.

In our study, two discrepant results were reported; unfortunately, neither of the patients could be re-traced for repeat testing during the study window. However, it is important to note that the Xpert® HCV VL Fingerstick assay cartridges provided were the first generation research use only versions, which is likely to have a lower quality control in comparison to the recent fully CE marked commercially available assay.

Existing literature evaluating the performance of the Xpert® HCV VL assay in Cambodia has provided compelling evidence to support its use in such resource-limited settings. However, this study was conducted using plasma, which still requires a laboratory set up for plasma separation. Our study adds to the limited literature addressing the use of HCV NAT point-of-care tests in sub-Saharan Africa, raising the potential for Xpert® HCV VL Fingerstick assay to provide a further simplified solution to existing issues related to HCV diagnosis. In addition, we add our findings to the limited data supporting the use of the Xpert® platform in HCV genotype 4.

In recent times, the challenge for HCV point-of-care diagnostic assay development has been to match conventional laboratory-based NAT lower-limits of detection, which are as low as 15 IU/mL. The clinical relevance of relaxing this threshold has recently been tested in a global dataset, which identified a HCV RNA cut-off of 1316 IU/mL would identify 97% of cases. In addition, a study evaluating VL in DAA treatment relapse suggested that 97% of cases had a VL of greater than 10 000 IU/mL. The European Association for the Study of Liver has also recently endorsed a HCV NAT diagnostic cut-off of 1000 IU/mL for LMICs in order to increase HCV RNA point-of-care uptake.

Despite these recommendations, very limited real-world validation of HCV RNA point-of-care exists in LMICs and none in Africa have been published so far. The WHO has pre-qualified the Xpert® HCV VL assay, which not only ensures

![Figure 2](image) Breakdown of testing errors for both Xpert® HCV RNA plasma and Fingerstick assay (n = 71). HCV, hepatitis C virus; VL, viral load.
quality control but also is often a prerequisite for donor funded programmes. However, despite having a lower limit of detection significantly below recommendations (40 IU/mL) from a whole blood sample, the Xpert® HCV VL Fingerstick assay is yet to receive WHO pre-qualification.

There are a number of advantages specific to the GeneXpert® platform that make it an attractive option to improving the diagnosis of communicable infections across sub-Saharan Africa. Firstly, it is already a well-established technology used as the first-line diagnostic test for Tuberculosis (TB) in sub-Saharan Africa. In response to the WHO 2010 recommendations for TB diagnosis, an exponential rise in Xpert® modules to 21,549 was recorded between 2010 and 2015 in 122 ‘high-burden developing countries’ (HBDC). Furthermore, recent data from Nigeria confirm that there are over 1500 modules distributed across the nation. Thus, it is not only a familiar technology but also widely disseminated across the continent. This is particularly key in resource-limited settings as in most cases it would avoid the potentially prohibitive USD$17 000 instrument cost. Secondly, Cepheid has agreed to honour a uniform assay cost of USD$14.90 for HBDC, which may allow government programmes to pool finances and negotiate the best rate possible when purchasing cartridges. Thirdly, the platform can be used simultaneously to test for other endemic viral infections. For example, the WHO have prequalified the Xpert® HIV VL assay, which has a lower limit of detection of 38 IU/mL. Its performance and utility have also been tested in a rural community-based project in Botswana, reporting a sensitivity of 98.6%. More recently, Cepheid have launched a hepatitis B VL assay, which may contribute a much-needed tool to aid treatment decision-making and monitoring in resource-limited settings.

Although the role for HCV RNA point-of-care is becoming clearer in aiding diagnosis of viraemic individuals, there have
been little data to support its confirming of post-treatment response. As part of their Xpert® HCV VL Fingerstick assay validation, Lamoury and colleagues reported a sensitivity of 81.8% and a specificity of 100% for the Xpert® HCV VL Fingerstick assay to detect HCV RNA in a small group of patients on DAA treatment (n = 16). Additional work in larger cohorts using HCV core antigen as a surrogate measure for viraemia to evaluate sustained virological response at 12 weeks post-therapy have reported high levels of concordance with HCV RNA levels. In order to truly decentralise and simplify future efforts to improve linkage to HCV treatment in marginalised settings, it is clear that HCV RNA point-of-care will play an important role. Therefore, it is vital that further evaluation of the utility, performance and cost-effectiveness of HCV RNA point-of-care, such as Xpert® HCV VL Fingerstick assay, is conducted to confirm HCV treatment response in resource-limited settings.

It is also important to appreciate the role of HCV point-of-care diagnostic technology to enhance the linkage-to-care. There are emerging examples of the Xpert® HCV VL assay improving screening and linkage-to-care from a community programme in Egypt and marginalised PWID screening in Australia and, reporting treatment uptake of 93% and 44% respectively. A unique feature of the Xpert® HCV VL Fingerstick assay is a rapid turn-around time (60 minutes) making a same visit HCV RNA diagnosis a real possibility, which could potentially further improve linkage to treatment.

Despite our study providing further empirical evidence supporting the utility of the Xpert® HCV VL Fingerstick assay to reliably diagnose viraemic HCV in resource-limited settings, there are some notable limitations. Firstly, although this is a sizeable evaluation of Xpert® HCV VL Fingerstick assay performance, it was conducted in a hospital environment and further evaluation in different challenging settings (such as rural areas) is still warranted. Secondly, the Xpert® HCV VL assay was used as the gold standard as there was no local access to conventional laboratory-based NAT testing. However, it is unlikely that this would have introduced any significant discrepancy as this assay is WHO pre-qualified and has demonstrated excellent performance in previous validation studies. Thirdly, as local genotyping was not available, only those with historic genotypes were reported in this study. However, though it is relevant from an epidemiological perspective to determine genotype, its clinical relevance has been minimised by the availability of pangenotypic DAs, as proposed in a recent algorithm for screening in LMIC settings. Finally, our conclusions are limited to PWID engaged in harm reduction and marginalised PWID screening in Australia and, reporting treatment uptake of 93% and 44% respectively. A unique feature of the Xpert® HCV VL Fingerstick assay is a rapid turn-around time (60 minutes) making a same visit HCV RNA diagnosis a real possibility, which could potentially further improve linkage to treatment.

Until recently, access to HCV NAT confirmation was considered a major obstacle to improving access to care in resource-limited settings. We provide evidence here that the Xpert® HCV VL Fingerstick assay is a technically feasible, cost-amenable and ultra-sensitive assay to simplify HCV NAT diagnosis in resource-limited settings and paves the way to facilitate the much-needed HCV treatment intervention in our challenging PWID setting in sub-Saharan Africa.

ACKNOWLEDGEMENTS
This study was supported by an Imperial College Wellcome Trust Centre Global Health Research Seed Grant. In addition, infrastructure support was provided by the Imperial College London NIHR Biomedical Facility. The authors thank all patients for their willingness to participate and staff members working MNH OAT clinic for their support in during the study. We also thank Cepheid for donating Xpert® HCV VL and FS cartridges. Cepheid has not contributed to the design of the study and the analysis of the results. We are also grateful to Rita Carvalho, project manager of the PROLIFICA programme (www.prolifica.africa).

CONFLICT OF INTEREST
The authors do not have any disclosures to report.

ORCID
Zameer Mohamed https://orcid.org/0000-0002-3713-0277

REFERENCES


